Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 13, 2008

View Archived Issues

Daiichi Sankyo updates recent activity

AVI initiates next-generation drug eluting stent trial with Global Therapeutics

Novexel commences phase II for NXL-104/ceftazidime combination in UTIs

Quigley completes phase IIb study of QR-333 in diabetic peripheral neuropathy

Vical completes enrollment in phase II CMV vaccine trial

Phase IIa results with INCB-018424 in rheumatoid arthritis lead to phase IIb trials

Phase I data reported for autoimmune disorders candidate LX-2931

RAPID data show radiographic activity in nonresponders, sustained benefits in extension study

HIV protease inhibitor saquinavir kills ovarian cancer cells

ACH-702: new data on preclinical antibacterial activity, pharmacokinetics

Pfizer reports on sulopenem prodrug antibiotics

Seroquel approved in Europe for new indications in bipolar disorder

Sevikar approved in Germany for hypertension

Sanofi-aventis reports new post hoc results from ATHENA trial of Multaq in AF/AFL

Boehringer announces results from the PETRO-Ex study of Pradaxa for stroke in AF

Yissum and BioLineRx enter license agreement for antihormone BL-5040 in IBD

Swissmedic approves ceftobiprole for complicated skin and soft tissue infections

Nymox reports positive results in 59-week study of NX-1207 for BPS

Novel antiobesity agents disclosed in recent patents

Recent Novartis patent discloses novel antiinflammatory agents

New diagnostic agents imparted by Merck Eprova

Antyra and Novo Nordisk sign licensing agreement for IGF antagonists

Ensemble and Roche extend collaboration for diagnostic technology in cancer therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...